1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,370 | 3,390 | 13.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12.25 | Biohit Oyj: New Study Shows Normal GastroPanel Result Safely Rules Out Need for Gastroscopy | 81 | GlobeNewswire (Europe) | Biohit Oyj Press Release8 December 2025 at 10:30 a.m. EEST
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy
Major Cost Savings Possible
A newly published clinical study... ► Artikel lesen | |
| 12.11.25 | Biohit Oyj: Chile's national cancer prevention strategy brings GastroPanel technology into public healthcare | 209 | GlobeNewswire (Europe) | Biohit Oyj Press Release12 November 2025 at 2:00 p.m. EEST
Chile's national cancer prevention strategy brings GastroPanel® technology into public healthcare
The Chilean Ministry of Health has introduced... ► Artikel lesen | |
| 06.08.25 | Biohit Oyj: Biohit Group Half Year Financial Report 2025 (unaudited) | 174 | GlobeNewswire (Europe) | BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2025 (unaudited)
Biohit Oyj Half Year Financial Report 6 August 2025 at 9:30 am local time (EET)
SUMMARY
January-June 2025
Revenue EUR 7.4 million (EUR 7.4... ► Artikel lesen | |
| 04.06.25 | Biohit Oyj: Decisions of the Annual General Meeting of Biohit Oyj | 146 | GlobeNewswire (Europe) | Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Decisions of the Annual General Meeting, June 4, 2025 at 6.00 pm local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held... ► Artikel lesen | |
| BIOHIT Aktie jetzt für 0€ handeln | |||||
| 12.02.25 | Biohit Oyj: Biohit Group Financial Statement Release 2024 | 157 | GlobeNewswire (Europe) | BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2024
Biohit Oyj Financial Statement Release 12 February 2025 at 9:30 am local time (EET)
SUMMARY
January-December 2024
Revenue EUR 14.3 million (EUR 13.1... ► Artikel lesen | |
| 16.01.25 | Biohit Oyj: BIOHIT secures European distribution rights for Biomedal's gluten immunogenic peptide tests | 244 | GlobeNewswire (Europe) | BIOHIT secures European distribution rights for Biomedal's gluten immunogenic peptide tests
Biohit Oyj Press release 16 January 2025 at 11.00 am local time (EEST)
BIOHIT is excited to announce an agreement... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 280,83 | +1,85 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 77,92 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 20,140 | -2,09 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| BEAM THERAPEUTICS | 34,550 | +2,55 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| BIONTECH | 92,05 | 0,00 % | mRNA Patentstreit: Bayer zieht BioNTech, Pfizer und Moderna vor Gericht | © Foto: Juan Vega - EUROPA PRESSBayer erhebt schwere Patentvorwürfe gegen die Hersteller der erfolgreichsten Corona-Impfstoffe. Im Zentrum steht eine mRNA-Technologie aus den 1980er-Jahren.Der Agrar-... ► Artikel lesen | |
| QIAGEN | 40,415 | -1,26 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,100 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,700 | -1,28 % | ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook | ||
| ALUMIS | 22,110 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,280 | +1,50 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 74,13 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,940 | -0,12 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,760 | -6,56 % | Harmony Biosciences: WAKIX-Umsatz soll 2026 die Marke von 1 Milliarde US-Dollar übersteigen | ||
| DYNE THERAPEUTICS | 17,040 | -2,41 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,75 | +2,90 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target |
Das Unternehmen BIOHIT OYJ kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,73 % bei einem Aktienkurs von 3,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOHIT OYJ finden Sie auf Wallstreet Online.